Revisiting the Bristol-Myers Squibb (BMY US) Bullish Investment Thesis After the Q3 Earnings Report.
In our first report onĀ Bristol Myers Squibb Co (BMY US), we presented our bullish contrarian thesis and considered the common stock undervalued for...
477 Views
Hanmi Pharmaceutical: This Korean Pharma Giant's Stock Could Rebound More than 50%.
Hanmi Pharm Co Ltd (128940 KS)Ā stock has fallen from recent highs after Boehringer pulled out of an oncology deal and short-sellers piled on the...
751 Views
Roche's Tecentriq Approved As Second-Line in Lung Cancer: Implications For Bristol-Myers Squibb
FDA approved Roche's (U.S. ADR, OTCBB: RHHBY) Tecentriq, a checkpoint inhibitor that targets PD-L1 as a second-line therapy in metastatic non-small...
308 Views
Big Pharma Fails to Heed Its Mistakes
GlaxoSmithKline and other big pharma companies have repeatedly been convicted and fined for unethical business practices - mainly offering bribes -...
305 Views
2016 US Elections Scenario Two: Donald Trump Wins
A US election fought under moderately favourable economic conditions, with a Republican electorate divided and openly unhappy with its...
269 Views